PDAC is not solely driven by KRAS (Kirsten Rat Sarcom Viral Oncogene Homolog) mutations but also by alterations in three other key oncogenes—TP53, CDKN2A, and SMAD4—which collectively shape the tumor’s biology and contribute to its resistance to treatment. This evidence concerns the gene KRAS and neoplasm.